Urologically Speaking: Top Content in Benign Prostatic Hyperplasia

Welcome back to Urology Times' LinkedIn newsletter, Urologically Speaking! In this issue, we'll be highlighting our most recent coverage of news and insights surrounding benign prostatic hyperplasia (BPH).

Take a look through some of the top stories below!

FDA approves label expansion for Rezūm Water Vapor Therapy for BPH

In June 2025, the FDA granted 510(k) clearance to a label expansion for the Rezūm System to broaden use of the device in patients with prostate volumes up to 150 g, a significant increase from the previous 30 g-80 g range.

"The indication expansion for Rezūm Therapy is clinically important in the US as it provides physicians and patients another treatment option that doesn’t require general anesthesia when treating large prostate glands (defined as 80-150 g by the American Urological Association),” said Ronald Morton , MD, chief medical officer, Urology, Boston Scientific. “Rezūm Therapy continues to offer its intended benefits: it is minimally invasive, suitable for ambulatory settings, and has no negative impact to sexual function."

Click here to read the full article.

Hear thoughts on the recent label expansion from Kevin McVary , MD, FACS, here.

Bilal Chughtai, MD, discusses pivotal trial of the Butterfly device for BPH

The Butterfly Prostatic Retraction device is currently under investigation in a prospective pivotal trial (NCT05341661) in men with lower urinary tract symptoms secondary to BPH.

In a recent interview with Urology Times®, Bilal Chughtai , MD, walked through the design and potential implications of the trial for clinical practice. 

Click here to watch the full video.

Water vapor therapy demonstrates superior outcomes vs pharmaceutical therapy for BPH

Data recently published in Urology suggest that water vapor therapy with Rezūm may be a more effective first-line treatment option compared with pharmaceutical therapy for patients with BPH.

Specifically, patients who underwent treatment with Rezūm demonstrated the lowest 5-year progression rate at 4.6%, compared with rates ranging from 7.5% to 19.3% among patients who received doxazosin, finasteride, combination therapy, or placebo. Further, water vapor therapy yielded superior initial improvements in lower urinary tract symptoms over pharmaceutical therapy, although this difference diminished over time.

Click here to read the full article.

Dean Elterman, MD, on the shift toward personalized care in BPH

The treatment landscape for BPH is shifting toward more personalized approaches to care, according to Dean Elterman, MD, MSc, FRCSC of the University of Toronto.

In a recent interview with Urology Times®, Elterman emphasized the growing need to align treatment decisions with patient-defined outcomes—particularly in terms of symptom relief and quality of life. He also highlighted a rising interest in first-line interventional therapies (FITs), a category of minimally invasive treatments designed to offer symptom control while preserving sexual function.

Click here to watch the full video.

Amy Krambeck, MD, on innovation and building strong programs in endourology

At the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada, Amy E. Krambeck, MD, of Northwestern Medicine presented a talk titled, “Innovation in endourology & building successful clinical programs.”

In a recent discussion with Urology Times, Krambeck recapped several key points from the session, touching on the ‘3 shields’ of research, education, and clinical excellence.

Click here to watch the full video.